{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:00:53Z","timestamp":1791928853329,"version":"4.3.4"},"reference-count":60,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"6","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest. Ophthalmol. Vis. Sci."],"published-print":{"date-parts":[[2025,6,4]]},"DOI":"10.1167\/iovs.66.6.14","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T11:30:39Z","timestamp":1749036639000},"page":"14","source":"Crossref","is-referenced-by-count":1,"title":["Impact of Second-Generation PDE 5 Inhibitor, Avanafil, on Retinal Function: Studies From Ex Vivo ERG"],"prefix":"10.1167","volume":"66","author":[{"given":"Sama","family":"Saeid","sequence":"first","affiliation":[{"name":"Department of Neuroscience and Biomedical Engineering, Aalto University, Espoo, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans","family":"Vinberg","sequence":"additional","affiliation":[{"name":"John A. Moran Eye Center, University of Utah, Salt Lake City, Utah, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Koskelainen","sequence":"additional","affiliation":[{"name":"Department of Neuroscience and Biomedical Engineering, Aalto University, Espoo, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrd4228","article-title":"Advances in targeting cyclic nucleotide phosphodiesterases","volume":"13","author":"Maurice","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1152\/physrev.00030.2010","article-title":"Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions","volume":"91","author":"Francis","year":"2011","journal-title":"Physiol Rev"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1210\/er.2013-1053","article-title":"Clinical and molecular genetics of the phosphodiesterases (PDEs)","volume":"35","author":"Azevedo","year":"2014","journal-title":"Endocr Rev"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41573-019-0033-4","article-title":"Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond","volume":"18","author":"Baillie","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1111\/odi.12275","article-title":"Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets","volume":"21","author":"Ahmad","year":"2015","journal-title":"Oral Dis"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1038\/sj.ijir.3901208","article-title":"Potency, selectivity, and consequences of nonselectivity of PDE inhibition","volume":"16","author":"Bischoff","year":"2004","journal-title":"Int J Impot Res"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"S252","DOI":"10.1038\/sj.bjp.0706495","article-title":"Phosphodiesterase inhibitors","volume":"147","author":"Boswell-Smith","year":"2006","journal-title":"Br J Pharmacol"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0079-6603(08)60718-7","article-title":"The molecular biology of cyclic nucleotide phosphodiesterases","volume":"63","author":"Conti","year":"1999","journal-title":"Prog Nucleic Acid Res Mol Biol"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1021\/acschemneuro.0c00106","article-title":"PDE-7 inhibitor BRL-50481 reduces neurodegeneration and long-term memory deficits in mice following sevoflurane exposure","volume":"11","author":"Chen","year":"2020","journal-title":"ACS Chem Neurosci"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"127097","DOI":"10.1016\/j.bmcl.2020.127097","article-title":"Novel PDE5 inhibitors derived from rutaecarpine for the treatment of Alzheimer's disease","volume":"30","author":"Huang","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"109694","DOI":"10.1016\/j.mehy.2020.109694","article-title":"A new approach at diabetic foot treatment: phosphodiesterase 5 inhibitors","volume":"141","author":"Bugday","year":"2020","journal-title":"Med Hypotheses"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3389\/fimmu.2020.00451","article-title":"Myeloid-derived suppressor cells as target of phosphodiesterase-5 inhibitors in host-directed therapeutics for tuberculosis","volume":"11","author":"Leukes","year":"2020","journal-title":"Front Immunol"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"113818","DOI":"10.1016\/j.bcp.2020.113818","article-title":"Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease","volume":"176","author":"Zuccarello","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/npr2.12108","article-title":"Combination of the phosphodiesterase 10A inhibitor, MR1916 with risperidone shows additive antipsychotic-like effects without affecting cognitive enhancement and cataleptic effects in rats","volume":"40","author":"Arakawa","year":"2020","journal-title":"Neuropsychopharmacol Rep"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"8485","DOI":"10.1021\/acs.jmedchem.0c00853","article-title":"Structure of human phosphodiesterase 5A1 complexed with avanafil reveals molecular basis of isoform selectivity and guidelines for targeting a-helix backbone oxygen by halogen bonding","volume":"63","author":"Hsieh","year":"2020","journal-title":"J Med Chem"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.eururo.2010.02.020","article-title":"Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation","volume":"57","author":"Hatzimouratidis","year":"2010","journal-title":"Eur Urol"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1743-6109.2009.01627.x","article-title":"Pharmacotherapy for erectile dysfunction","volume":"7","author":"Eardley","year":"2010","journal-title":"J Sex Med"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3390\/biomedicines9030291","article-title":"Visual side effects linked to sildenafil consumption: an update","volume":"9","author":"Aus\u00f3","year":"2021","journal-title":"Biomedicines"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1089\/jop.2005.21.305","article-title":"Effects of phosphodiesterase type 5 inhibitor sildenafil on retinal function in isolated superfused retina","volume":"21","author":"L\u00fcke","year":"2005","journal-title":"J Ocul Pharmacol Ther"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1517\/14740338.2016.1130126","article-title":"The safety and efficacy of avanafil, a new 2nd generation PDE5i: comprehensive review and meta-analysis","volume":"15","author":"Corona","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1167\/iovs.05-0257","article-title":"Efficacy and selectivity of phosphodiesterase-targeted drugs in inhibiting photoreceptor phosphodiesterase (PDE6) in retinal photoreceptors","volume":"46","author":"Zhang","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/andr.12683","article-title":"The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue","volume":"7","author":"Zucchi","year":"2019","journal-title":"Andrology"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"e29390","DOI":"10.4161\/cl.29390","article-title":"Current understanding of signal amplification in phototransduction","volume":"4","author":"Arshavsky","year":"2014","journal-title":"Cell Logist"},{"key":"bib24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1146\/annurev.physiol.64.082701.102229","article-title":"G proteins and phototransduction","volume":"64","author":"Arshavsky","year":"2002","journal-title":"Annu Rev Physiol"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-3-030-96405-4","article-title":"Photoreceptor phosphodiesterase (PDE6): structure, regulatory mechanisms, and implications for treatment of retinal diseases","volume":"1371","author":"Cote","year":"2022","journal-title":"Adv Exp Med Biol"},{"key":"bib26","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1113\/jphysiol.1992.sp019111","article-title":"A quantitative account of the activation steps involved in phototransduction in amphibian photoreceptors","volume":"449","author":"Lamb","year":"1992","journal-title":"J Physiol"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"100772","DOI":"10.1016\/j.preteyeres.2019.07.005","article-title":"Cellular mechanisms of hereditary photoreceptor degeneration\u2014focus on cGMP","volume":"74","author":"Power","year":"2020","journal-title":"Prog Retin Eye Res"},{"key":"bib28","first-page":"435","article-title":"Future prospects in the treatment of erectile dysfunction: focus on avanafil","volume":"5","author":"Alwaal","year":"2011","journal-title":"Drug Des Devel Ther"},{"key":"bib29","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2147\/VHRM.S26712","article-title":"Avanafil for treatment of erectile dysfunction: review of its potential","volume":"29","author":"Evans","year":"2012","journal-title":"Vasc Health Risk Manag"},{"key":"bib30","doi-asserted-by":"publisher","first-page":"629","DOI":"10.2147\/TCRM.S419408","article-title":"The efficacy and safety of avanafil during a treatment of male erectile dysfunction: a systematic review and meta-analysis of randomized controlled trials","volume":"19","author":"Warli","year":"2023","journal-title":"Ther Clin Risk Manag"},{"key":"bib31","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.eururo.2015.03.031","article-title":"Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis","volume":"68","author":"Chen","year":"2015","journal-title":"Eur Urol"},{"key":"bib32","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1517\/13543784.2010.518955","article-title":"Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction","volume":"19","author":"Limin","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"bib33","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.juro.2013.01.017","article-title":"Avanafil, a highly selective phosphodiesterase type 5 inhibitor for erectile dysfunction, shows good safety profiles for retinal function and hemodynamics in anesthetized dogs","volume":"190","author":"Mochida","year":"2013","journal-title":"J Urol"},{"issue":"4","key":"bib34","first-page":"1","article-title":"Closed-perfusion transretinal ERG setup for preclinical drug and nanostructure testing","volume":"72","author":"Saeid","year":"2024","journal-title":"IEEE Trans Biomed Eng"},{"key":"bib35","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4103\/ijabmr.IJABMR_339_18","article-title":"Avanafil inhibits the contractility of the isolated caprine detrusor muscle","volume":"9","author":"Dhruva","year":"2019","journal-title":"Int J Appl Basic Med Res"},{"key":"bib36","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10633-009-9191-8","article-title":"Dimethyl sulphoxide dose-response on rat retinal function","volume":"119","author":"Tsai","year":"2009","journal-title":"Doc Ophthalmol"},{"key":"bib37","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1017\/S0952523800174036","article-title":"In search of the visual pigment template","volume":"17","author":"Govardovskii","year":"2000","journal-title":"Vis Neurosci"},{"key":"bib38","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.visres.2007.11.005","article-title":"Mouse cone photoresponses obtained with electroretinogram from the isolated retina","volume":"48","author":"Heikkinen","year":"2008","journal-title":"Vis Res"},{"key":"bib39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.taap.2018.03.002","article-title":"Electrophysiological determination of phosphodiesterase-6 inhibitor inhibition constants in intact mouse retina","volume":"345","author":"Turunen","year":"2018","journal-title":"Toxicol Appl Pharmacol"},{"key":"bib40","doi-asserted-by":"publisher","first-page":"19599","DOI":"10.1073\/pnas.2001776117","article-title":"Elevated energy requirement of cone photoreceptors","volume":"117","author":"Ingram","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"bib41","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/j.1442-9071.2009.02070.x","article-title":"Phosphodiesterase inhibitors and the eye","volume":"37","author":"Kerr","year":"2009","journal-title":"Clin Exp Ophthalmol"},{"key":"bib42","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.ajo.2003.11.081","article-title":"Visual short-term effects of Viagra: double-blind study in healthy young subjects","volume":"137","author":"J\u00e4gle","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"bib43","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40942-020-00241-0","article-title":"Effects of phosphodiesterase type 5 inhibitors on choroid and ocular vasculature: a literature review","volume":"6","author":"Da Cruz","year":"2020","journal-title":"Int J Retina Vitreous"},{"key":"bib44","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.acthis.2018.03.002","article-title":"An immunohistochemical and ultrastructural analysis of the retina in tadalafil (Cialis) treated rats","volume":"120","author":"Sarhan","year":"2018","journal-title":"Acta Histochem"},{"key":"bib45","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/sj.eye.6702908","article-title":"Expression of the PDE5 enzyme on human retinal tissue: new aspects of PDE5 inhibitors ocular side effects","volume":"22","author":"Foresta","year":"2008","journal-title":"Eye"},{"key":"bib46","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.preteyeres.2008.03.003","article-title":"Regulation of ON bipolar cell activity","volume":"27","author":"Snellman","year":"2008","journal-title":"Prog Retin Eye Res"},{"key":"bib47","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1038\/sj.ijir.3901212","article-title":"Characteristics of photoreceptor PDE (PDE6): similarities and differences to PDE5","volume":"16","author":"Cote","year":"2004","journal-title":"Int J Impot Res"},{"key":"bib48","doi-asserted-by":"publisher","first-page":"9407","DOI":"10.1039\/D0RA00569J","article-title":"LC-MS\/MS determination of avanafil and its metabolites in rat plasma and brain: pharmacokinetic study after oral administration and transdermal film application","volume":"10","author":"Kammoun","year":"2020","journal-title":"RSC Adv"},{"key":"bib49","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.clinthera.2010.06.011","article-title":"Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers","volume":"32","author":"Jung","year":"2010","journal-title":"Clin Ther"},{"key":"bib50","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.1002\/jps.22610","article-title":"Comparison of drug permeabilities across the blood\u2013retinal barrier, blood\u2013aqueous humor barrier, and blood\u2013brain barrier","volume":"100","author":"Toda","year":"2011","journal-title":"J Pharm Sci"},{"key":"bib51","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1038\/emboj.2009.284","article-title":"Structural basis of phosphodiesterase 6 inhibition by the C-terminal region of the ?-subunit","volume":"28","author":"Barren","year":"2009","journal-title":"EMBO J"},{"key":"bib52","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.2174\/138161206778343064","article-title":"Expression, distribution and regulation of phosphodiesterase 5","volume":"12","author":"Lin","year":"2006","journal-title":"Curr Pharm Des"},{"key":"bib53","doi-asserted-by":"publisher","first-page":"111128","DOI":"10.1016\/j.biopha.2020.111128","article-title":"Phosphodiesterase 5 (PDE5): structure-function regulation and therapeutic applications of inhibitors","volume":"134","author":"Ahmed","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"bib54","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1124\/jpet.120.000486","article-title":"A p97\/valosin-containing protein inhibitor drug CB-5083 has a potent but reversible off-target effect on phosphodiesterase-6","volume":"378","author":"Leinonen","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"key":"bib55","doi-asserted-by":"publisher","first-page":"31541","DOI":"10.1074\/jbc.M109.018606","article-title":"Probing the catalytic sites and activation mechanism of photoreceptor phosphodiesterase using radiolabeled phosphodiesterase inhibitors","volume":"284","author":"Liu","year":"2009","journal-title":"J Biol Chem"},{"key":"bib56","doi-asserted-by":"publisher","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","article-title":"DrugBank 6.0: the DrugBank Knowledgebase for 2024","volume":"52","author":"Knox","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"bib57","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1085\/jgp.116.6.795","article-title":"The role of steady phosphodiesterase activity in the kinetics and sensitivity of the light-adapted salamander rod photoresponse","volume":"116","author":"Nikonov","year":"2000","journal-title":"J Gen Physiol"},{"key":"bib58","doi-asserted-by":"publisher","first-page":"e0245161","DOI":"10.1371\/journal.pone.0245161","article-title":"Sildenafil-evoked photoreceptor oxidative stress in vivo is unrelated to impaired visual performance in mice","volume":"16","author":"Berkowitz","year":"2021","journal-title":"PLoS One"},{"key":"bib59","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1167\/iovs.18-26433","article-title":"Transducin1, phototransduction and the development of early diabetic retinopathy","volume":"60","author":"Liu","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib60","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1167\/iovs.63.13.22","article-title":"Transducin-deficient rod photoreceptors evaluated with optical coherence tomography and oxygen consumption rate energy biomarkers","volume":"63","author":"Berkowitz","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Investigative Ophthalmology & Visual Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2803073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:31:58Z","timestamp":1791927118000},"score":1,"resource":{"primary":{"URL":"https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2803073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,2]]}},"URL":"https:\/\/doi.org\/10.1167\/iovs.66.6.14","relation":{},"ISSN":["1552-5783"],"issn-type":[{"value":"1552-5783","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,4]]}}}